Want to see EWTX full AI Analyst Report?
EWTX Stock Chart & Stats
$34.43
-$0.39(-1.54%)
At close: 4:00 PM EST
$34.43
-$0.39(-1.54%)
Day’s Range― - ―
52-Week Range$12.30 - $48.40
Previous CloseN/A
Volume107.81K
Average Volume (3M)1.50M
Market Cap
$4.28B
Enterprise Value$2.88K
Total Cash (Recent Filing)$499.56M
Total Debt (Recent Filing)$3.79M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Aug 06, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding107,593,000
10 Day Avg. Volume1,171,419
30 Day Avg. Volume1,501,843
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.89
Price to Sales (P/S)0.00
P/FCF Ratio-17.76
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$50.60Price Target Upside46.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.98
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low leverage and a sizable asset base provide a durable funding cushion to support multi-year clinical programs. This reduces near-term financing pressure, lowers dilution risk, and gives management flexibility to prioritize development timelines and partnerships through pivotal milestones.
Asset Sale Boosts Financial FlexibilityThe sevasemten sale materially strengthens liquidity and is expected to fully fund lead-program development through potential approval. This structural capital infusion reduces runway risk, enables sustained R&D investment, and permits strategic focus on building a cardiovascular franchise without immediate reliance on external dilution.
Advancing, De-risking Lead Cardiovascular AssetPositive short-term Phase 2 results and a committed Phase 3 start indicate de-risking of EDG-7500 as a lead asset. Durable impact: a successful pivotal program would validate strategy, materially increase approval probability, and shift the company from research to late-stage development with clearer regulatory pathways.
Bears Say
Pre-revenue CompanyEdgewise remains pre-revenue and lacks commercial products, so long-term viability depends on clinical success, milestone receipts, or partnerships. This structural dependence increases execution risk and means the company must convert clinical progress into approvals and revenue to sustain growth beyond financing events.
Sustained High Cash BurnConsistent, large negative operating and free cash flow necessitates funding to maintain programs. Even with recent proceeds, prolonged or expanded development timelines could exhaust resources, force prioritization, or require additional financing, which can dilute shareholders and constrain long-term program breadth.
Concentrated Pipeline RiskSelling muscular dystrophy assets narrows the company’s therapeutic diversity and concentrates outcomes on a few cardiovascular programs. Structurally, this increases company-level binary risk: setbacks in a lead program would have outsized impact on prospects, valuation drivers, and partner interest over the medium term.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics, Inc.’s price range in the past 12 months?
Edgewise Therapeutics, Inc. lowest stock price was $12.30 and its highest was $48.40 in the past 12 months.
What is Edgewise Therapeutics, Inc.’s market cap?
Edgewise Therapeutics, Inc.’s market cap is $4.28B.
When is Edgewise Therapeutics, Inc.’s upcoming earnings report date?
Edgewise Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Edgewise Therapeutics, Inc.’s earnings last quarter?
Edgewise Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.485 by $0.025.
Is Edgewise Therapeutics, Inc. overvalued?
According to Wall Street analysts Edgewise Therapeutics, Inc.’s price is currently Undervalued.
Does Edgewise Therapeutics, Inc. pay dividends?
Edgewise Therapeutics, Inc. does not currently pay dividends.
What is Edgewise Therapeutics, Inc.’s EPS estimate?
Edgewise Therapeutics, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Edgewise Therapeutics, Inc. have?
Edgewise Therapeutics, Inc. has 107,593,000 shares outstanding.
What happened to Edgewise Therapeutics, Inc.’s price movement after its last earnings report?
Edgewise Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.485. Following the earnings report the stock price went down -3.812%.
Which hedge fund is a major shareholder of Edgewise Therapeutics, Inc.?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.60 (46.96% Upside)
$50.60 (46.96% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 522.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 17.4%
Last 30 Days ▲ 17.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
189.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Company Description
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$50.60
▲(46.96% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
0.94% Insiders
13.90% Mutual Funds
0.23% Other Institutional Investors
75.25% Public Companies and
Individual Investors